SCHEMBL6583329

SCHEMBL6583329

CCCc1ccc2cccc(N)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.46
PLG P00747 1/20 0.46
PLAU P00749 1/20 0.46
PLAT P00750 1/20 0.46
KLK1 P06870 1/20 0.46
PRSS1 P07477 1/20 0.46
ALDH1A1 P00352 4/20 0.45
CYP3A4 P08684 3/20 0.45
HPGD P15428 3/20 0.45
TSHR P16473 2/20 0.45
HSD17B10 Q99714 2/20 0.45
KEAP1 Q14145 1/20 0.45
POLB P06746 3/20 0.44
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
KDM4E B2RXH2 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
TDP2 O95551 1/20 0.44
MAPT P10636 1/20 0.44
CASP6 P55212 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5749553 0.87 PARP1 (0.49) PARP1SKP2
SCHEMBL5749294 0.87 PARP1 (0.49) PARP1SKP2
SCHEMBL5747458 0.87 PARP1 (0.49) PARP1SKP2
SCHEMBL5745524 0.85 CYP1A2 (0.53) F2PLGPLAUPLATKLK1
SCHEMBL19583348 0.80 CNR1 (0.50) CYP3A4POLBKMT2AMEN1GAA
SCHEMBL19583381 0.79 CYP1A2 (0.56) ALDH1A1CYP3A4HPGDTSHRHSD17B10
SCHEMBL18243537 0.79 MEN1 (0.42) CYP3A4POLBKMT2AMEN1GAA
SCHEMBL28831388 0.78 PLAU (0.53) F2PLGPLAUPLATKLK1
SCHEMBL15715989 0.77 F2 (0.45) F2PLGPLAUPLATKLK1
SCHEMBL28499910 0.76 CYP1A2 (0.53) ALDH1A1CYP3A4HPGDTSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040259875-A1 Amine derivatives BAYER HEALTHCARE AG (DE) 2004-12-23 US disclosed
EP-1414788-A1 NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS Bayer HealthCare AG (DE) 2004-05-06 EP disclosed
WO-2003014064-A1 NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS BAYER HEALTHCARE AG (DE) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259875-A1 Amine derivatives AVPR1A, GRIN1, OPRL1 F2 4433/4885PLG 3443/4885PLAU 2785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.